Jump to content

Kite Pharma

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ek009 (talk | contribs) at 21:19, 11 October 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Kite Pharma, Inc.
Company typeSubsidiary
IndustryBiopharmaceutical
Founded2009; 15 years ago (2009)
FounderArie Belldegrun and Joshua Kazam
FateAcquired by Gilead Sciences
Headquarters
Santa Monica
,
California
Key people
ProductsCancer immunotherapy
Number of employees
2,000
ParentGilead Sciences
Websitewww.kitepharma.com
Footnotes / references
Key People,[1][2] Founder[2]

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically-engineered autologous T cell therapy with chimeric antigen receptors (CAR-T). Based in Santa Monica, California, it was acquired by Gilead Sciences.

History

The company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer.[1][3] Belldegrun had a co-founder in Joshua Kazam, who took on the role of Director.[2]

On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal,[4] equating to $180 cash per share. The deal was expected to add the promising CAR-T candidate to Gilead's existing portfolio.[5] The acquisition was completed in October 2017,[6] when Kite Pharma's therapy, Yescarta (axicabtagene ciloleucel), became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.[7] This form of immunotherapy was originally developed by the U.S. National Cancer Institute and the company pays the government to support continuing research.[8]

In 2017, MIT Technology Review ranked Kite Pharma 7th in its annual list of the preceding year's 50 Smartest Companies.[9]

Lead product

Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.[10] It garnered a US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL).[11] It was approved for use in the United States under the brand name YESCARTA in October 2017.[2]

Development history

2012

In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) for the development and commercialization of products for the treatment of multiple cancer indications.[12]

2013

In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite's most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma, known as diffuse large B cell lymphoma (DLBCL).[13] The clinical data were presented at the 55th American Society of Hematology Annual Meeting.[14]

2014

In March, the company announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's proposed therapy for DLBCL.[15]

In June, Kite Pharma entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the NY-ESO-1 antigen for the treatment of cancers expressing NY-ESO-1.[16]

In August, Kite Pharma announced findings from its ongoing clinical trial: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL.[17]

2015

In January, Kite Pharma and Amgen entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's extensive array of cancer targets.[18][19]

In May, Kite Pharma announced that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive Non-Hodgkin's Lymphoma has been treated.[20]

In June, Kite Pharma and bluebird bio, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies.[21]

In July, Kite Pharma and the Leukemia & Lymphoma Society announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive Non-Hodgkin's Lymphoma.[22]

In September, Kite Pharma announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI.[23]

In October, Kite Pharma announced that it has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T cell receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others.[24] In the same month, Kite Pharma announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences (AIS), a privately held biotechnology startup, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. This collaboration will accelerate Kite's efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor micro-environment.[25][26]

In December, Kite Pharma announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemia's.[10] In the same month, Kite Pharma and GE Global Research announced they will partner to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy. Kite and GE Global Research—GE's centralized R&D hub—said they aim to increase the availability of engineered T-cell therapies by speeding up development of automation technologies that have the potential to lower costs, operate faster, and minimize variability.[27] Also in December, Kite announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL).[11]

2016

In January, it was announced that Kite Pharma has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias.[28] Moreover, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection.[29]

In March, Kite Pharma has announced that it would be collaborating with Genentech, in order to evaluate the safety and efficacy of two of its novel therapies. The target population for the tests would be patients with non-Hodgkin Lymphoma. The therapies in question, KTE-C19 and atezolizumab, would be tested in combination with each other.[30]

In June, Kite Pharma and Cell Design Labs, Inc. announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate Cell Design Labs' molecular “on/off switch” technology.[31] Also in June, Kite Pharma announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers.[32]

In July, Kite Pharma announced that it has entered into an exclusive, worldwide license agreement with The Regents of the University of California, on behalf of the University of California, Los Angeles (UCLA), for technology to advance the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells.[33]

In December, Kite Pharma and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA-approved, including axicabtagene ciloleucel (formerly known as KTE-C19), Kite's lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma.[34]

2017

In March, Kite announced results a clinical trial of CAR-T cells in around a hundred people with advanced Non-Hodgkin lymphoma.[35]

In April, Kite has won the ‘Clinical Trial Result of the Year’ award for its CAR-T trial of Axicabtagene Ciloleucel in patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs.[36]

In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its axicabtagene ciloleucel (KTE-C19) for two types of non-Hodgkin's lymphoma (NHL).[37]

Business history

In March 2011, Kite Pharma received $15 million in Series A venture cash.[38]

In May 2013, Kite Pharma completed a $35 million financing of Series A preferred stock.[39][40][41]

In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes.[42][43]

In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock.[44]

In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million.[45][46][47] The company listed on the NASDAQ Global market under the symbol “KITE.”

In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million.[48]

In March 2015, Kite Pharma acquired T-Cell Factory (TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. Per the deal, Kite Pharma has obtained license agreements with IBA GmbH, Sanquin Blood Supply Foundation and the Netherlands Cancer Institute (NKI), which include the rights to select new intellectual property related to T-cell receptors (TCRs) developed at the NKI. Additionally, the TCF acquisition will allow Kite Pharma to access the European manufacturing facilities, paving way for the company to initiate development programs in the EU and build its presence in the region.[49][50]

In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million.[51]

In January 2017, Kite Pharma announced that it has partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments, of the $250 million, Kite said it would receive $50 million as upfront payment.[52] Also in January, Kite Pharma announced that it had formed a joint venture with Fosun Pharmaceutical to develop and commercialize its cancer treatment in China. Kite Pharma said it would receive an upfront payment of $40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million.[53]

On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for US$11.9 billion in cash ($180.00 per share).[54] The purchase was subsequently completed for the announced price on October 3, 2017.[55][2]

Allogene Therapeutics

Following the sale of Kite to Gilead, Kite's founders and its CMO struck a deal in February 2018 with Pfizer to develop CAR-T therapeutics, leading to the creation of Allogene Therapeutics. The three former Kite executives subsequently hired into Allogene a number of people who left Kite after its sale. The notion behind Allogene was to create a 'next generation CAR-T' which was not tailored to a single individual, as YESCARTA was, but rather could be used in multiple patients, an allogeneic CAR-T. Pfizer received a 25% stake in Allogene and two seats on the company's board, while Allogene received rights to sixteen pre-clinical CAR-T assets and one Phase 1 allogeneic CAR-T clinical asset. Allogene's Series A funding was US$300 million, including Texas Pacific Group, University of California, Two River—and even Gilead as participants, among others. In October 2019, Allogene's initial public offering netted US$324 million and a capital valuation of US$3 billion.[2]

See also

References

  1. ^ a b "Management Team". Kite Pharma. Archived from the original on 17 July 2017. Retrieved 2 June 2016.[self-published source]
  2. ^ a b c d e f Wright, Rob (January 31, 2020). "Allogene Therapeutics—The Juggernaut Built On Kite's Flight". Life Science Leader (Online). Pennsylvania: VertMarkets. Retrieved 15 Feb 2020.
  3. ^ Puzzanghera, Jim (August 28, 2017). "Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion". Los Angeles Times. Retrieved 2022-07-13.
  4. ^ Grover, Natalie; Erman, Michael (28 August 2017). "Gilead to buy Kite for promising cancer therapies in $12 billion deal". Reuters. Retrieved 19 Dec 2019. Gilead Sciences Inc (GILD.O) agreed to buy Kite Pharma Inc KITE.O in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.
  5. ^ Palmer, Eric (28 August 2017). "Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy". FiercePharma. Framingham, Massachusetts: Questex. Retrieved 19 Dec 2019. Gilead Sciences CEO John Milligan, under pressure from a flagging hep C franchise, has finally pulled the trigger on a deal aimed at growing sales in a new field.
  6. ^ "Gilead Sciences Completes Acquisition of Kite Pharma, Inc" (Press release). Gilead Sciences. 3 October 2017. Retrieved 19 Dec 2019.[self-published source]
  7. ^ "Kite's Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy" (Press release). Gilead Sciences. 18 October 2017. Retrieved 19 Dec 2019.[self-published source]
  8. ^ Richtel, Matt; Pollack, Andrew (2016-12-19). "Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits". The New York Times. ISSN 0362-4331. Retrieved 2022-07-13.
  9. ^ Staff (27 June 2017). "What are the 50 Smartest Companies?". MIT Technology Review. Retrieved 19 Dec 2019. 7 Kite Pharma
  10. ^ a b "Kite Pharma (KITE) Announces Initiation of KTE-C19 Phase 1/2". StreetInsider.com. 2 December 2015. Retrieved 19 Dec 2019. Kite Pharma (NASDAQ: KITE) announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with r/r ALL.
  11. ^ a b "Kite Pharma (KITE) Announces KTE-C19 for NHL Granted FDA Breakthrough Therapy Designation". StreetInsider.com. 7 December 2015. Retrieved 19 Dec 2019. Kite Pharma, Inc. (Nasdaq: KITE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL).
  12. ^ "Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products" (Press release). Kite Pharma. 16 October 2012. Archived from the original on 9 August 2014. Retrieved 15 Aug 2014.[self-published source]
  13. ^ "Kite Pharma's Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin's Lymphoma" (Press release). Kite Pharma. 7 December 2013. Archived from the original on 9 August 2014. Retrieved 15 Aug 2014.[self-published source]
  14. ^ "Donor-derived allogeneic T cells may cause regression of B-cell malignancies". Meeting News Coverage. Healio. Thorofare, New Jersey: SLACK Incorporated. 7 December 2013. Retrieved 19 Dec 2019. The infusion of donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells caused regression of highly treatment-resistant B-cell malignancies after allogeneic hematopoietic stem cell transplantation, according to study results presented at the ASH Annual Meeting and Exposition.
  15. ^ "Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product" (Press release). Kite Pharma. 31 March 2014. Archived from the original on 12 January 2015. Retrieved 19 May 2014.[self-published source]
  16. ^ "Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications" (Press release). Kite Pharma. 6 June 2014. Archived from the original on 11 August 2014. Retrieved 8 Jun 2014.[self-published source]
  17. ^ Ro, Sam (26 August 2014). "Biotech Stock Kite Pharma Explodes Higher After Good News About Its Non-Hodgkin Lymphoma Drug". Business Insider. Retrieved 27 August 2014.
  18. ^ "". Reuters. 5 January 2015. Retrieved 21 January 2015.
  19. ^ "Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies". Kite Pharma. 5 January 2015. Retrieved 21 January 2015.
  20. ^ "Kite Pharma Announces That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) ". MarketWatch. 21 May 2015. Retrieved 7 July 2015.
  21. ^ "Kite Pharma & Bluebird Bio To Co-develop T Cell Cell Therapy Products". NASDAQ. 22 June 2015. Retrieved 7 July 2015.
  22. ^ "Kite Pharma (KITE), Leukemia & Lymphoma Society Enter Into Collaboration". StreetInsider.com. 1 July 2015. Retrieved 7 July 2015.
  23. ^ "Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)". Kite Pharma. 14 September 2015. Retrieved 20 October 2015.
  24. ^ "Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE". FiereceBiotech. 20 October 2015. Retrieved 20 October 2015.
  25. ^ "Kite to spend as much as $530 million on rights to AIS programs ". ThePharmaLetter. 28 October 2015. Retrieved 28 October 2015.
  26. ^ Demmitt, Jacob (28 October 2015). "Seattle’s Alpine Immune Sciences licenses cancer treatment to Kite Pharma for up to $530M". GeekWire. Retrieved 28 October 2015.
  27. ^ "Kite Pharma, GE Global Research Partner on T-Cell Therapy Manufacturing". Genetic Engineering & Biotechnology News. 3 December 2015. Retrieved 7 December 2015.
  28. ^ "Kite Pharma (KITE), NCI Expand Clinical and Research Partnership". TheStreet.com. 7 January 2015. Retrieved 7 January 2015.
  29. ^ "Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers". FierceBiotech. 13 January 2016. Retrieved 13 January 2016.
  30. ^ Sandford, Miles (18 March 2016). "Kite Pharma Inc (NASDAQ:KITE) To Begin a Collaborative Study on KTE-C19". Journal Transcript. Retrieved 18 March 2016.
  31. ^ "Kite Pharma (KITE), Cell Design Labs Enter Research Collaboration for Next-Gen CAR Product Candidates". StreetInsider.com. 2 June 2016. Retrieved 2 June 2016.
  32. ^ "Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)". BusinessWire. 20 June 2016. Retrieved 20 June 2016.
  33. ^ "Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies ". BusinessWire. 25 July 2016. Retrieved 26 July 2016.
  34. ^ "Kite Pharma (KITE) Enters Strategic Partnership with Vitruvian Networks". StreetInsider.com. 13 December 2016. Retrieved 14 December 2016.
  35. ^ Whipple, Tom (2017-03-01). "New gene therapy 'shrinks tumours like ice cubes'". The Times. Retrieved 2017-03-01.
  36. ^ "Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards". Yahoo Finance. 6 April 2017. Retrieved 7 April 2017.
  37. ^ Taylor, Phil (1 August 2017). "Kite files first CAR-T candidate in Europe". PMLive. Retrieved 9 August 2017.
  38. ^ “Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors”. Kite Pharma . 9 March 2011. Retrieved 29 July 2014.
  39. ^ “Kite Pharma Completes $35 Million Series A Preferred Stock Financing”. Kite Pharma . 15 May 2013. Retrieved 15 August 2014.
  40. ^ Orbach, Meir (18 May 2014). "טיפול לסרטן שפותח ברחובות נמצא בדרך לנאסד"ק" (In Hebrew). Calcalist (Tel Aviv). Retrieved 19 May 2014.
  41. ^ McBride, Ryan (15 May 2013). "UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies". FierceBiotech. Retrieved 19 May 2014.
  42. ^ " Kite Pharma, Inc. Completes $50 Million Mezzanine Private Financing". Kite Pharma. 28 April 2014. Retrieved 19 May 2014.
  43. ^ Carroll, John (28 April 2014). "Immuno-oncology specialist Kite adds $50M in new financing". FierceBiotech. Retrieved 19 May 2014.
  44. ^ “Kite Pharma Files Registration Statement for Proposed Initial Public Offering”. Kite Pharma. 19 May 2014. Retrieved 19 May 2014.
  45. ^ “Kite Pharma Announces Pricing of Initial Public Offering”. Kite Pharma. 20 June 2014. Retrieved 15 August 2014.
  46. ^ Calia, Michael (20 June 2014). "Kite Pharma Soars Above IPO Price on First Day of Trading". The Wall Street Journal. Retrieved 21 June 2014.
  47. ^ “Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares”. Kite Pharma. 23 June 2014. Retrieved 15 August 2014.
  48. ^ "Kite Pharma Announces Pricing of Follow-On Offering". Reuters. 10 December 2014. Retrieved 10 December 2015.
  49. ^ "Kite Pharma Acquires T-Cell Factory for $21M Up Front". Genetic Engineering & Biotechnology News. 18 March 2015. Retrieved 18 March 2015.
  50. ^ Zacks.com (18 March 2015)."Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog". NASDAQ. Retrieved 18 March 2015.
  51. ^ "Kite Pharma Announces Pricing of Public Offering of Common Stock". Reuters. 10 December 2015. Retrieved 10 December 2015.
  52. ^ Grover, Divya (9 January 2017). "Kite Pharma partners with Japan's Daiichi for cancer therapy". Reuters. Retrieved 10 January 2017.
  53. ^ Mukhopadhyay, Akankshita (10 January 2017). "Kite, Fosun Pharma form JV in China for cancer treatment". Reuters. Retrieved 10 January 2017.
  54. ^ "Gilead | Investors | News Release". investors.gilead.com (Press release). Retrieved 2017-08-28.[self-published source][permanent dead link‍]
  55. ^ "Gilead Sciences Completes Acquisition of Kite Pharma, Inc". Newsroom (Press release). Gilead. October 3, 2017. Retrieved 15 Feb 2020.[self-published source]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kite_Pharma&oldid=1115515475"